![Adipogen/Delanzomib [CEP-18770]/AG-CR1-3673-M005/5 mg](https://www.ebiomall.cn/images/adipogen/ag-cr1-3673.png)
Adipogen/Delanzomib [CEP-18770]/AG-CR1-3673-M005/5 mg
商品编号：
AG-CR1-3673-M005
品牌：
Adipogen Inc
市场价：
¥2400.00
美元价：
1440.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Product Details | |
|---|---|
| Synonyms | NPH 007098; CT 47098; CIP 18770; [(1R)-1-[[(2S,3R)-3-Hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]butanoyl]amino]-3-methylbutyl]boronic acid |
| Product Type | Chemical |
| Properties | |
| Formula | C21H28BN3O5 |
| MW | 413.3 |
| CAS | 847499-27-8 |
| Purity Chemicals | ≥98% |
| Appearance | White solid. |
| Solubility | Soluble in DMSO (20mg/ml) or ethanol (20mg/ml). Slightly soluble in chloroform or methanol. Poorly soluble in water (<1mg l).=""> |
| Other Product Data | Note: Warming and sonication may be required when dissolving the compound in the solvent of choice. Stock solutions are stable for at least 1 month when stored at -20°C. |
| InChi Key | SJFBTAPEPRWNKH-CCKFTAQKSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Keep cool and dry. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
- Potent, selective, reversible orally bioavailable proteasome inhibitor. Synthetic P2 threonine boronic acid.
- Targets the chymotrypsin-like β5 subunit of the constitutive 20S proteasome (IC50=3.8nM). Cross-reacts and inhibits the caspase-like/peptidyl-glutamyl peptide-hydrolyzing (PGPH) β1 subunit (IC50=~70nM).
- Displays similar potency for the chymotrypsin-like activity of the proteasome compared to bortezomib. Exhibits a favorable cytotoxicity profile toward normal human epithelial cells, bone marrow progenitors and bone marrow-derived stromal cells relative to bortezomib (Prod. No. AG-CR1-3602).
- Anticancer compound effective against multiple myeloma in vivo.
- In vitro, blocks the growth of representative human solid and hematological tumor cell lines (IC50s=5.6-34nM).
- Shown to down-modulate NF-κB, induce apoptosis, inhibit angiogenesis and M-CSF-RANKL-induced osteoclastogenesis.
Product References
- Discovery of a Potent, Selective, and Orally Active Proteasome Inhibitor for the Treatment of Cancer: B.D. Dorsey, et al.; J. Med. Chem. 51, 1068 (2008)
- CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib: R. Piva, et al.; Blood 111, 2765 (2008)
- The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan: E. Sanchez, et al.; Br. J. Haematol. 148, 569 (2010)
- Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE: M.M. Seavey, et al.; Int. Immunopharmacol. 12, 257 (2012)
- Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib: C.R. Berkers, et al.; Mol. Pharm. 9, 1126 (2012)
- Molecular mechanisms of acquired proteasome inhibitor resistance: A.J. Kale & B.S. Moore; J. Med. Chem. 55, 10317 (2012)
- A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma: E. Gallerani, et al.; Eur. J. Cancer 49, 290 (2013)
- Proteasome inhibitors in the treatment of multiple myeloma: A. McBride & P.Y. Ryan; Expert Rev. Anticancer Ther. 13, 339 (2013) (Review)
- Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma: D.T. Vogl, et al.; Leuk. Lymphoma 58, 1872 (2017)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
